Identifying biomarkers for intervertebral disc degeneration and pain
Development of New Diagnostic, Prognostic and Therapeutic Strategies in the Field of Degenerative Disc Disease: Identification of Biomarkers and Molecular Targets Involved in Discogenic Pain and Neuroinflammation
This study is trying to find new ways to treat low back pain by looking at how certain substances in the body affect disc degeneration.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 160 (estimated) |
| Sex | All |
| Sponsor | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT06349226 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on understanding the mechanisms behind intervertebral disc degeneration and associated pain, which affects a significant portion of the population. It aims to investigate the role of sphingolipid metabolism and its impact on inflammation and degeneration of the intervertebral discs. By isolating cells from disc tissue and examining biomarkers, the study seeks to uncover new therapeutic targets for treating discogenic pain. The findings could lead to improved management strategies for patients suffering from low back pain due to disc degeneration.
Who should consider this trial
Good fit: Ideal candidates for this study are patients experiencing disc degeneration due to conditions such as spondylolisthesis or herniated intervertebral discs.
Not a fit: Patients with spinal infections will not benefit from this study as they are excluded from participation.
Why it matters
Potential benefit: If successful, this study could lead to the development of new therapies that effectively alleviate discogenic pain and improve patient quality of life.
How similar studies have performed: Other studies have explored similar mechanisms in disc degeneration, but this specific focus on sphingolipid metabolism is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with disc degeneration for spondylolisthesis, herniated intervertebral disc, and other causes of disc degeneration Exclusion Criteria: * Spinal infection
Where this trial is running
Milan
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico — Milan, Italy (Recruiting)
Study contacts
- Principal investigator: Mauro Pluderi, MD — Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Neurosurgery Unit
- Study coordinator: Giovanni Marfia, MD, PhD
- Email: giovanni.marfia@policlinico.mi.it
- Phone: 0255034268
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.